Dogwood Therapeutics Secures License from Serpin Pharma to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a clinical-stage biotechnology company developing new medicines to treat pain and neuropathy, recently announced that in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma’s intravenous (IV) formulation of SP16 to manage cancer related pain (CRP) including a broad range of chemotherapy induced neuropathy symptoms.

Serpin Pharma has discovered the active portion of A1AT responsible for both the anti-inflammatory (analgesic) activity as well as tissue repair, and this active portion is represented by SP16. SP16 is a first-in-class LRP1 agonist which has demonstrated both anti-inflammatory and neural repair activity that has the potential to treat chemotherapy-induced peripheral neuropathy (CIPN). SP16 IV is the focus of a forthcoming Phase 1b CIPN study that is fully funded by the National Cancer Institute, reflecting the uniqueness of this approach, as well as the extraordinary unmet medical need associated with this debilitating cancer-related condition.

Pursuant to an exclusive licensing agreement Serpin Pharma, Inc. and its designated affiliates will receive 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock (with a conversion ratio of preferred to common of 1:10,000) (the “Preferred Stock”) which collectively represents 7.31% of the Dogwood’s common stock, on a fully diluted basis which assumes conversion of all series of outstanding preferred stock of the Dogwood including any transaction fees.

Rimon partner, David Case, advised Serpin Pharma on SP16 IP license and protection matters of the transaction, while Rimon partner Mark C Lee advised on the securities issues.

We congratulate Serpin Pharma and Dogwood Therapeutics on this exciting development!

Rimon’s team of Life Sciences attorneys have extensive experience working with clients in the biotechnology, pharmaceutical, medical device, vape- and wellness-product industries. We have represented Life Sciences clients ranging from start-up companies to multinational publicly traded clients in connection with both their corporate and litigation matters. In terms of corporate representation, Rimon counsels and defends Life Sciences clients in securities offerings (including angel investments, venture financings, private placements, and public offerings), mergers and acquisitions, employment and compensation law, licensing, intellectual property litigation, patent procurement and counseling, and numerous complex corporate transactions.  Read more here